journal article·2019

MRI-visible and pH-sensitive micelles loaded with doxorubicin for hepatoma treatment

Bo Li, Mingyue Cai, Liteng Lin, Weitong Sun, Zhimei Zhou, Shiyin Wang, Yong Wang, Kangshun Zhu, Xintao Shuai

Biomaterials Science· Volume 7· Issue 4
Publisher page

Abstract

Emerging pH-sensitive polymeric nanocarriers carrying therapeutic drugs are bringing about new opportunities for the effective treatment of cancer. A big challenge remains though to develop pH-sensitive polymers, which is hard to achieve via introducing only one kind of pH-sensitive chemical structure with a specific pKa. Consequently, in this study, an amphiphilic block copolymer, poly(ethylene glycol)-b-poly(β-benzyl l-aspartate) (mPEG-PBLA), was synthesized, and its PBLA block was aminolyzed by N,N-diisopropylamino ethylamine (DIP) and N,N-dibutalamino ethylamine (DBA) at different molar ratios. The copolymer mPEG-PAsp(DBA75%&DIP25%) (PPAP75%) with an appropriate pKa was screened out to form a pH-sensitive micelle, which could encapsulate a high content of the hydrophobic anticancer drug doxorubicin (DOX) and magnetic resonance imaging (MRI) contrast agent superparamagnetic iron oxide nanoparticles (SPIONs) at neutral pH, but disassemble rapidly under weak acidic conditions. The micellar nanodrug was efficiently taken up by HepG2 cells and intracellular DOX release was readily triggered inside acidic lysosomal compartments to allow migration of the free drug to the cell nucleus. In vivo fluorescence and MR bimodal imaging showed that the pegylated nanodrug with a suitable size and weak positive charge could stay longer in the blood circulation and extravasate preferentially into a tumor. The nanodrug not only exhibited high cytotoxicity in HepG2 cells but also significantly prolonged the survival time of tumor-bearing mice, thereby demonstrating the great potential of this pH-sensitive and MRI-visible micelle for the effective treatment of cancer.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of Interventional Radiology

Department of Minimally Invasive Interventional Radiology

and Department of Radiology

the Second Affiliated Hospital of Guangzhou Medical University

Guangzhou

Pharmaceutical college of Jiamusi University

Jiamusi University

Jiamusi

China

PCFM Lab of Ministry of Education

School of Materials Science and Engineering

Sun Yat-sen University

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Fundo para o Desenvolvimento das Ciências e da Tecnologia

References (58)

Show source-provided references
1. Siegel · CA-Cancer J. Clin. · 2014 · 64 · 910.3322/caac.21208 ↗
2. Pramanik · Mater. Sci. Eng., C · 2016 · 68 · 32710.1016/j.msec.2016.05.014 ↗
3. Wiradharma · Nano Today · 2009 · 4 · 30210.1016/j.nantod.2009.06.001 ↗
4. Otsuka · Adv. Drug Delivery Rev. · 2012 · 64 · 24610.1016/j.addr.2012.09.022 ↗
5. M. E. Davis , Z.Chen and D. M.Shin , Nanoparticle therapeutics: an emerging treatment modality for cancer , in Nanoscience And Technology: A Collection of Reviews from Nature Journals , World Scientific , 2010 , pp. 239–250
6. Kichler · J. Gene Med. · 2001 · 3 · 13510.1002/jgm.173 ↗
7. Ai · Adv. Mater. · 2005 · 17 · 194910.1002/adma.200401904 ↗
8. H. Maeda , The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting , Advances in enzyme regulation , 2001
9. Torchilin · Nat. Rev. Drug Discovery · 2014 · 13 · 81310.1038/nrd4333 ↗
10. Björnmalm · ACS Nano · 2017 · 11 · 959410.1021/acsnano.7b04855 ↗
11. Guo · J. Polym. Sci., Part A: Polym. Chem. · 2016 · 54 · 352510.1002/pola.28252 ↗
12. Cai · Appl. Mater. Today · 2018 · 11 · 20710.1016/j.apmt.2018.02.003 ↗
13. Gottesman · FEBS Lett. · 2006 · 580 · 99810.1016/j.febslet.2005.12.060 ↗
14. Choi · Cancer Cell Int. · 2005 · 5 · 3010.1186/1475-2867-5-30 ↗
15. Greish · J. Drug Targeting · 2007 · 15 · 45710.1080/10611860701539584 ↗
16. Zhang · Nano LIFE · 2010 · 1 · 16310.1142/S179398441000016X ↗
17. Teo · Nanomedicine · 2017 · 13 · 43110.1016/j.nano.2016.09.016 ↗
18. Volk · Br. J. Cancer · 1993 · 68 · 49210.1038/bjc.1993.375 ↗
19. Yin · J. Controlled Release · 2008 · 126 · 13010.1016/j.jconrel.2007.11.014 ↗
20. Ma · J. Am. Chem. Soc. · 2014 · 136 · 1108510.1021/ja5053158 ↗
21. Wang · Nat. Mater. · 2014 · 13 · 20410.1038/nmat3819 ↗
22. Mi · Nat. Nanotechnol. · 2016 · 11 · 72410.1038/nnano.2016.72 ↗
23. Wang · Nat. Commun. · 2015 · 6 · 852410.1038/ncomms9524 ↗
24. Lin · Mol. Pharmaceutics · 2015 · 12 · 286910.1021/acs.molpharmaceut.5b00060 ↗
25. Zhou · Int. J. Pharm. · 2015 · 487 · 8110.1016/j.ijpharm.2015.03.081 ↗
26. Nakanishi · React. Funct. Polym. · 2007 · 67 · 136110.1016/j.reactfunctpolym.2007.08.009 ↗
27. Feng · PLoS One · 2014 · 9 · e10073210.1371/journal.pone.0100732 ↗
28. Moon · Polym. Int. · 2013 · 62 · 121810.1002/pi.4412 ↗
29. Dai · Angew. Chem., Int. Ed. · 2011 · 50 · 940410.1002/anie.201103806 ↗
30. Li · Chem. Soc. Rev. · 2012 · 41 · 259010.1039/c1cs15246g ↗
31. Janib · Adv. Drug Delivery Rev. · 2010 · 62 · 105210.1016/j.addr.2010.08.004 ↗
32. Khemtong · Cancer Res. · 2009 · 69 · 165110.1158/0008-5472.CAN-08-3231 ↗
33. Liao · Eur. J. Radiol. · 2011 · 80 · 699
34. Nasongkla · Nano Lett. · 2006 · 6 · 242710.1021/nl061412u ↗
35. Zhang · J. Biomed. Nanotechnol. · 2014 · 10 · 21610.1166/jbn.2014.1729 ↗
36. Neal · J. Pharm. Sci. · 1998 · 87 · 124210.1021/js970462j ↗
37. Daly · Tetrahedron Lett. · 1988 · 29 · 585910.1016/S0040-4039(00)82209-1 ↗
38. Yokoyama · Bioconjugate Chem. · 1992 · 3 · 29510.1021/bc00016a007 ↗
39. Sun · J. Am. Chem. Soc. · 2004 · 126 · 27310.1021/ja0380852 ↗
40. Duan · J. Biomed. Nanotechnol. · 2016 · 12 · 211210.1166/jbn.2016.2321 ↗
41. Chen · Int. J. Nanomed. · 2012 · 7 · 359
42. Shen · Nanomedicine · 2009 · 5 · 19210.1016/j.nano.2008.09.003 ↗
43. Alexis · Mol. Pharmaceutics · 2008 · 5 · 50510.1021/mp800051m ↗
44. Fang · Eur. J. Pharm. Sci. · 2006 · 27 · 2710.1016/j.ejps.2005.08.002 ↗
45. Levchenko · Int. J. Pharm. · 2002 · 240 · 9510.1016/S0378-5173(02)00129-1 ↗
46. Stylianopoulos · Biophys. J. · 2010 · 99 · 134210.1016/j.bpj.2010.06.016 ↗
47. Lieleg · Biophys. J. · 2009 · 97 · 156910.1016/j.bpj.2009.07.009 ↗
48. Chtryt · J. Bioact. Compat. Polym. · 2001 · 16 · 42710.1106/FDUM-1LXE-WGJ9-BYVW ↗
49. Luo · J. Controlled Release · 2012 · 162 · 18510.1016/j.jconrel.2012.06.027 ↗
50. Johnson · Biomacromolecules · 2013 · 14 · 143410.1021/bm400089m ↗
51. Wang · Nanoscale · 2014 · 6 · 763510.1039/c4nr00843j ↗
52. Xiao · Colloids Surf., B · 2016 · 141 · 8310.1016/j.colsurfb.2016.01.016 ↗
53. Wu · Biomaterials · 2014 · 35 · 824910.1016/j.biomaterials.2014.06.014 ↗
54. K. Greish , Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting , in Cancer Nanotechnology , Springer , 2010 , pp. 25–37
55. Cai · Biomacromolecules · 2017 · 18 · 210210.1021/acs.biomac.7b00445 ↗
56. Chen · J. Controlled Release · 2013 · 169 · 17110.1016/j.jconrel.2013.01.001 ↗
57. Zhang · Arch. Immunol. Ther. Exp. · 2009 · 57 · 43510.1007/s00005-009-0051-8 ↗
58. Chatterjee · Cardiology · 2010 · 115 · 15510.1159/000265166 ↗